Panbela Therapeutics, Inc. (OTC:PBLA) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Greetings and welcome to the Panbela Therapeutics Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference over to your host, Jam ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 88-2805017 (Sta ...

Future studies will be designed to evaluate the effects of SBP-101 in combination with other polyamine metabolism modulators as well as with immune modulators. The results suggest that SBP-101 in common with doxorubicin may have a role in the clinical management of ovarian cancer, in particular, the platinum-resistant population where few options exist. These studies are the basis for moving into a clinical trial program in ovarian cancer with the goal of developing effective novel therapeutics in combinati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-39468 Panbela Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 88-2805017 (St ...

James Carbonara - Hayden IR Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Good day, everyone. And welcome to the Panbela Therapeutics Fourth Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions-andcomments after the presentation. Before I turn the call over to Dr. Simpson, please note that statements made on this call that are not historical facts may be forward-looking statements. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39468 PANBELA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 88-2805017 (State or other jurisdiction (IRS Emp ...

Panbela Therapeutics, Inc. (OTCQB:PBLA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - CEO Susan Horvath - CFO Conference Call Participants Tony Butler - ROTH Capital Operator Good day, and welcome to the Panbela Therapeutics Third Quarter 2022 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, James Carbonara. James, the floor is yours. James Carbonara Thank you. And once again, ...

Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Tony Butler – ROTH Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Panbela Therapeutics Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After managementÂ's prepared remarks, there will be ...

Panbela Therapeutics Inc. (OTCQB:PBLA) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants James Carbonara – Managing Partner-Hayden IR, Inc. Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Robin Garner – Craig-Hallum Tony Butler – Roth Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Panbela Therapeutics First Quarter 2022 Earnings Call. At this time, all participants are ...

Panbela Therapeutics Inc. (OTCQB:PBLA) Q4 2021 Earnings Conference Call March 24, 2022 4:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - President & Chief Executive Officer Susan Horvath - Vice President & Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim group Tony Butler - ROTH Capital Robin Garner - Craig-Hallum Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within ...